# US 2012/0237999 A1 · Herpes simplex viruses and methods of viral replication

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0237999 A1
- Document ID: US20120237999A1
- Status: Published application
- Kind: A1
- Application number: 13/417,708
- Filed: 2012-03-12
- Published: 2012-09-20
- Earliest claimed: 2007-02-16
- Assignees: Virttu Biologics Limited
- Inventors: Joe Conner; Susanne Moira Brown
- Web page: https://patentgrep.com/patent/US20120237999A1

## CPC

- C07K 14/4703: {Inhibitors; Suppressors}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/86: Viral vectors
- A61K 35/13: Tumour cells, irrespective of tissue of origin (tumour vaccines A61K39/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2710/16643: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide.

## Claims

### Claim 1

A method of replicating herpes simplex virus (HSV) in vitro, the method comprising providing in vitro a cell or cells having excess ING4 polypeptide and contacting the cell(s) with HSV capable of infecting the cell(s).

### Claim 2 (depends on 1)

The method of claim 1, wherein the cell(s) express ING4 polypeptide from a vector transfected into the cell(s).

### Claim 3 (depends on 1)

The method of claim 1, wherein the cell(s) express ING4 polypeptide from a heterologous construct comprising a nucleic acid sequence encoding an ING4 polypeptide.

### Claim 4 (depends on 3)

The method of claim 3, wherein said nucleic acid sequence is operably linked to a regulatory nucleotide sequence.

### Claim 5 (depends on 3)

The method of claim 3, wherein expression of said nucleic acid sequence encoding ING4 polypeptide is constitutive.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cell(s) overexpress endogenous ING4 polypeptide.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cell(s) have been contacted with ING4 polypeptide.

### Claim 8 (depends on 1)

The method of claim 1, wherein the HSV is selected from the group consisting of HSV-1 strain 17, a mutant of HSV-1 strain 17, HSV1716, a mutant of HSV1716, HSV1716ING4, HSV-1 strain F, and HSV-1 strain F mutant G207.

### Claim 9

A method for the in vitro replication of herpes simplex virus (HSV), the method comprising providing a cell or cells having excess ING4, infecting the cell(s) with HSV, culturing the cell(s) in vitro, and harvesting viral progeny from the cell(s).

### Claim 10 (depends on 9)

The method of claim 9, wherein the cell(s) express ING4 polypeptide from a vector transfected into the cell(s).

### Claim 11 (depends on 9)

The method of claim 9, wherein the cell(s) express ING4 polypeptide from a heterologous construct comprising a nucleic acid sequence encoding an ING4 polypeptide.

### Claim 12 (depends on 11)

The method of claim 11, wherein said nucleic acid sequence is operably linked to a regulatory nucleotide sequence.

### Claim 13 (depends on 11)

The method of claim 11, wherein expression of said nucleic acid sequence encoding ING4 polypeptide is constitutive.

### Claim 14 (depends on 9)

The method of claim 9, wherein the cell(s) overexpress endogenous ING4 polypeptide.

### Claim 15 (depends on 9)

The method of claim 9, wherein the cell(s) have been contacted with ING4 polypeptide.

### Claim 16 (depends on 9)

The method of claim 9, wherein the HSV is selected from the group consisting of HSV-1 strain 17, a mutant of HSV-1 strain 17, HSV1716, a mutant of HSV1716, HSV1716ING4, HSV-1 strain F, and HSV-1 strain F mutant G207.

### Claim 17

A cell, in vitro or in vivo, infected with a herpes simplex virus, which cell has an excess of ING4 polypeptide.

### Claim 18 (depends on 17)

A cell according to claim 17, wherein the cell expresses ING4 polypeptide from a heterologous construct comprising a nucleic acid sequence encoding an ING4 polypeptide.

### Claim 19 (depends on 17)

A cell according to claim 17, wherein the cell overexpresses endogenous ING4 polypeptide or wherein the cell has been contacted with ING4 polypeptide.

### Claim 20

A cell, in vitro, having an excess of ING4 polypeptide.
